Atrium Therapeutics Stock Forward View - Relative Strength Index
| RNADelisted Stock | USD 13.79 0.04 0.29% |
Atrium Therapeutics Common's Relative Strength Index reference page summarizes the forecasted price and model accuracy metrics derived from daily trading data. This reference information is provided for analytical context.
This Relative Strength Index forecast data for Atrium Therapeutics Common is sourced from the most recent available trading data and is intended solely as reference information. Relative Strength Index Analysis Today
Atrium Therapeutics Common has current Relative Strength Index of 4.88.| Volatility | Backtest | Information Ratio |
Atrium Therapeutics Trading Date Momentum
| On March 18 2026 Atrium Therapeutics Common was traded for 13.79 at the closing time. Highest Atrium Therapeutics's price during the trading hours was 13.99 and the lowest price during the day was 13.65 . There was no trading activity during the period 0.0. Lack of trading volume on the 18th of March 2026 did not affect price variability. The overall trading delta to current price is -0.15% . |
| Compare Atrium Therapeutics to competition |
Other Forecasting Options for Atrium Therapeutics
The movement of Atrium price is the central consideration for investors deciding whether to enter or hold a position. Noise in Atrium Stock price charts can make it difficult to distinguish meaningful trends from random fluctuations.Atrium Therapeutics Related Equities
The following equities are related to Atrium Therapeutics within the Health Care space and can be used for peer comparison, relative valuation, or portfolio diversification. Comparing Atrium Therapeutics against peers on metrics such as P/E, margins, and return on equity helps contextualize its positioning and identify relative strengths or weaknesses.
| Risk & Return | Correlation |
Atrium Therapeutics Market Strength Events
Investors use market strength indicators for Atrium Therapeutics to evaluate how the stock performs relative to broader market trends. These indicators support more precise timing of Atrium Therapeutics Common positions, helping investors maximize return and minimize poorly-timed trades.
Atrium Therapeutics Risk Indicators
A careful analysis of Atrium Therapeutics' basic risk indicators helps investors understand the risk environment surrounding atrium stock. This understanding is an essential input for forecasting Atrium Therapeutics' future price and for deciding how to manage the associated investment risk.
| Mean Deviation | 2.77 | |||
| Standard Deviation | 9.93 | |||
| Variance | 98.56 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Atrium Therapeutics
Coverage intensity for Atrium Therapeutics Common matters because narrative visibility can influence sentiment, participation, and volatility around the name. This is most useful when investors want to understand why a security is suddenly drawing more public discussion.
Contributor Headline
Latest Perspective From Macroaxis
Atrium Therapeutics Short Properties
Reviewing short-oriented indicators for Atrium Therapeutics Common is useful because long and short participants often create very different signals for timing and volatility. Used correctly, these measures can help investors decide when hedging or timing discipline may matter more than conviction alone.
| Common Stock Shares Outstanding | 137.7 M | |
| Cash And Short Term Investments | 1.7 B |
Use Historical Fundamental Analysis of Atrium Therapeutics to cross-verify projections for Atrium Therapeutics. The view supplies historical context for the projection discussion. Atrium Therapeutics currently shows ROE of -43.98%, market cap of 11.24 Billion. This analysis of Atrium Therapeutics works best as a complementary layer when evaluating how the security fits in a broader portfolio. The supplemental views below help investors decide how Atrium Therapeutics complements or overlaps with existing portfolio holdings. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Other Consideration for investing in Atrium Stock
Atrium Therapeutics liquidity profile may be thinner following delisting.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |